173 related articles for article (PubMed ID: 32183159)
41. BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.
Cuyàs E; Corominas-Faja B; Martín MM; Martin-Castillo B; Lupu R; Brunet J; Bosch-Barrera J; Menendez JA
Oncotarget; 2017 May; 8(21):35019-35032. PubMed ID: 28388533
[TBL] [Abstract][Full Text] [Related]
42. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
43. Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Kotsopoulos J; Singer C; Narod SA
Breast Cancer Res Treat; 2017 Jan; 161(1):11-16. PubMed ID: 27783278
[TBL] [Abstract][Full Text] [Related]
44. RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.
Azim HA; Peccatori FA; Brohée S; Branstetter D; Loi S; Viale G; Piccart M; Dougall WC; Pruneri G; Sotiriou C
Breast Cancer Res; 2015 Feb; 17():24. PubMed ID: 25849336
[TBL] [Abstract][Full Text] [Related]
45. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer.
Kiechl S; Schramek D; Widschwendter M; Fourkala EO; Zaikin A; Jones A; Jaeger B; Rack B; Janni W; Scholz C; Willeit J; Weger S; Mayr A; Teschendorff A; Rosenthal A; Fraser L; Philpott S; Dubeau L; Keshtgar M; Roylance R; Jacobs IJ; Menon U; Schett G; Penninger JM
Oncotarget; 2017 Jan; 8(3):3811-3825. PubMed ID: 28002811
[TBL] [Abstract][Full Text] [Related]
46. Hypoxia induces RANK and RANKL expression by activating HIF-1α in breast cancer cells.
Tang ZN; Zhang F; Tang P; Qi XW; Jiang J
Biochem Biophys Res Commun; 2011 May; 408(3):411-6. PubMed ID: 21514280
[TBL] [Abstract][Full Text] [Related]
47. RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies.
Leibbrandt A; Penninger JM
Adv Exp Med Biol; 2009; 649():100-13. PubMed ID: 19731623
[TBL] [Abstract][Full Text] [Related]
48. Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system.
Afhüppe W; Sommer A; Müller J; Schwede W; Fuhrmann U; Möller C
J Steroid Biochem Mol Biol; 2009 Jan; 113(1-2):105-15. PubMed ID: 19130882
[TBL] [Abstract][Full Text] [Related]
49. RANKL-induced c-Src activation contributes to conventional anti-cancer drug resistance and dasatinib overcomes this resistance in RANK-expressing multiple myeloma cells.
Mashimo K; Tsubaki M; Takeda T; Asano R; Jinushi M; Imano M; Satou T; Sakaguchi K; Nishida S
Clin Exp Med; 2019 Feb; 19(1):133-141. PubMed ID: 30291461
[TBL] [Abstract][Full Text] [Related]
50. RANKL and RANK: From Mammalian Physiology to Cancer Treatment.
Rao S; Cronin SJF; Sigl V; Penninger JM
Trends Cell Biol; 2018 Mar; 28(3):213-223. PubMed ID: 29241686
[TBL] [Abstract][Full Text] [Related]
51. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis.
Zhang Z; Jimi E; Bothwell AL
J Immunol; 2003 Oct; 171(7):3620-6. PubMed ID: 14500659
[TBL] [Abstract][Full Text] [Related]
52. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines.
Naidu VG; Dinesh Babu KR; Thwin MM; Satish RL; Kumar PV; Gopalakrishnakone P
Chem Biol Interact; 2013 Apr; 203(2):467-79. PubMed ID: 23333834
[TBL] [Abstract][Full Text] [Related]
53. Development of Small-Molecules Targeting Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Receptor Activator of Nuclear Factor-κB (RANK) Protein-Protein Interaction by Structure-Based Virtual Screening and Hit Optimization.
Jiang M; Peng L; Yang K; Wang T; Yan X; Jiang T; Xu J; Qi J; Zhou H; Qian N; Zhou Q; Chen B; Xu X; Deng L; Yang C
J Med Chem; 2019 Jun; 62(11):5370-5381. PubMed ID: 31082234
[TBL] [Abstract][Full Text] [Related]
54. Osteoclast regulation of osteoblasts via RANK‑RANKL reverse signal transduction in vitro.
Zhang S; Wang X; Li G; Chong Y; Zhang J; Guo X; Li B; Bi Z
Mol Med Rep; 2017 Oct; 16(4):3994-4000. PubMed ID: 28731168
[TBL] [Abstract][Full Text] [Related]
55. Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma.
Steven A; Leisz S; Fussek S; Nowroozizadeh B; Huang J; Branstetter D; Dougall WC; Burchardt M; Belldegrun AS; Seliger B; Pantuck A; Kroeger N
Urol Oncol; 2018 Nov; 36(11):502.e15-502.e24. PubMed ID: 30170981
[TBL] [Abstract][Full Text] [Related]
56. Porphyrin Derivatives Inhibit the Interaction between Receptor Activator of NF-κB and Its Ligand.
Chypre M; Madel MB; Chaloin O; Blin-Wakkach C; Morice C; Mueller CG
ChemMedChem; 2017 Oct; 12(20):1697-1702. PubMed ID: 28885764
[TBL] [Abstract][Full Text] [Related]
57. Cripto-1 ablation disrupts alveolar development in the mouse mammary gland through a progesterone receptor-mediated pathway.
Klauzinska M; McCurdy D; Rangel MC; Vaidyanath A; Castro NP; Shen MM; Gonzales M; Bertolette D; Bianco C; Callahan R; Salomon DS; Raafat A
Am J Pathol; 2015 Nov; 185(11):2907-22. PubMed ID: 26429739
[TBL] [Abstract][Full Text] [Related]
58. Expression and Distribution of Receptor Activator of Nuclear Factor Kappa B, Receptor Activator of Nuclear Factor Kappa B Ligand, and Osteoprotegerin in Periradicular Cysts.
Armada L; Marotta Pdos S; Pires FR; Siqueira JF
J Endod; 2015 Aug; 41(8):1281-7. PubMed ID: 25956608
[TBL] [Abstract][Full Text] [Related]
59. RANKL/RANK-beyond bones.
Hanada R; Hanada T; Sigl V; Schramek D; Penninger JM
J Mol Med (Berl); 2011 Jul; 89(7):647-56. PubMed ID: 21445556
[TBL] [Abstract][Full Text] [Related]
60. Novel RANKL DE-loop mutants antagonize RANK-mediated osteoclastogenesis.
Wang Y; van Assen AHG; Reis CR; Setroikromo R; van Merkerk R; Boersma YL; Cool RH; Quax WJ
FEBS J; 2017 Aug; 284(15):2501-2512. PubMed ID: 28627025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
